Trial Profile
A Non-interventional, Post-authorization Safety Study of Patients With Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2022
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Mantle-cell lymphoma
- Focus Adverse reactions
- Acronyms PASS MCL-005
- Sponsors Celgene Corporation
- 17 Apr 2019 Status changed from not yet recruiting to recruiting.
- 03 Sep 2018 New trial record